Richards Group (RIC) Q1 2026 earnings summary

Executive summary

• Q1 2026 consolidated revenue grew 5% year-over-year to CAD 105.7 million, led by strong healthcare segment growth and recent acquisitions, while packaging contracted sharply due to global headwinds and US tariffs.

• Gross margin improved to 44% (43.5%), with healthcare gross margin rising to 47% due to a shift toward OEM and aesthetics, while packaging margins contracted.

• EBITDA remained flat as increased operating expenses, particularly from OEM investments and product launches, offset margin gains.

• Major share buyback completed and acquisition of PharmaSystems Inc.'s CPG business for CAD 13.5 million, expanding the healthcare portfolio.

• Significant investments in marketing, personnel, and technology supported new product launches and CRM implementation.

Financial highlights

• Revenue increased by CAD 5 million year-over-year, with healthcare contributing CAD 14.6 million in growth, offset by a CAD 9.6 million decline in packaging.

• Gross margin rose by over CAD 5 million, with healthcare margins up 5–6.5 percentage points to 47%.

• EBITDA margin was 11.3%, with healthcare at 14.8% and packaging at 9%.

• Net income rose to $5.97 million from $5.11 million, with EPS up to $0.53 (basic) from $0.47.

• Adjusted free cash flow conversion dropped to 63% from 81%, with free cash flow at CAD 7.5 million, down from CAD 9.8 million.

Outlook and guidance

• Packaging is expected to remain challenged for the next three quarters due to inventory backlogs, macroeconomic headwinds, and higher freight rates.

• Management expects continued healthcare growth, both organic and via acquisitions, with ongoing international expansion and new verticals such as dental and ortho.

• Operating expenses are anticipated to decrease as OEM investments normalize and efficiencies are realized.

• Maintenance capital for 2026 is projected at $4.1 million, with continued IT and equipment investments.